NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Host Webinar on PC111 Antibody for Rare Skin Disorders
Scinai Immunotherapeutics (NASDAQ: SCNI) will host a webinar May 7 at 11:30 a.m. EST to discuss the treatment potential of Pincell’s novel monoclonal antibody, PC111, for rare skin conditions Pemphigus Vulgaris and SJS/TEN. The session will cover unmet medical needs, PC111’s mechanism targeting soluble Fas ligand, and development plans. The event follows Scinai’s March agreement to acquire Pincell and a related €12 million grant application under Poland’s FENG program. Panelists include executives from Scinai and Pincell, with a live Q&A segment. To view the full press release, visit https://nnw.fm/E19h6 About Scinai Immunotherapeutics Ltd. Scinai is a biopharmaceutical company with two…







